<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2171">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04681755</url>
  </required_header>
  <id_info>
    <org_study_id>7725</org_study_id>
    <nct_id>NCT04681755</nct_id>
  </id_info>
  <brief_title>Rehabilitation Required Due to Clinical Disorders After Severe Covid-19 Infection</brief_title>
  <acronym>REHABCOV</acronym>
  <official_title>Rehabilitation Required Due to Functional Neurological Impairment and Respiratory Disorders After Severe SARS-CoV-2 Infection in ICU Units</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Due to the emergence of an epidemic cluster in Mulhouse, a city located 100 km south of&#xD;
      Strasbourg, Alsace was one of the first French regions to be affected by the coronavirus&#xD;
      (SARS-CoV-2 or COVID-19). As a result, all hospitals in the region, including both Strasbourg&#xD;
      University Hospitals, had to deal with the epidemic wave earlier and more intensely than the&#xD;
      rest of France. At the time of writing this article, 6 weeks after the start of the epidemic,&#xD;
      we have counted 998 hospital deaths in our region, i.e., an intrahospital mortality rate&#xD;
      linked to COVID-19 of 5.3 deaths per 10,000 inhabitants&#xD;
      (https://dashboard.covid19.data.gouv.fr/).&#xD;
&#xD;
      Currently, our intensive care unit still has a large number of patients hospitalized for&#xD;
      COVID-19. Some of these patients have severe damage to one or more organs, and in particular&#xD;
      a neurological or respiratory deficit suggesting that they will need post-resuscitation&#xD;
      rehabilitation. The primary aim is to assess the neurological disorder after severe&#xD;
      SARS-CoV-2 infection and the second is the respiratory impairment evaluation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 19, 2020</start_date>
  <completion_date type="Anticipated">May 19, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 19, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Retrospective analysis of the neurological disorder after severe SARS-CoV-2 infection</measure>
    <time_frame>The files analysed retrospectily from February 24, 2020 to April 15, 2020 will be examined]</time_frame>
  </primary_outcome>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Covid19</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patient with a SARS-CoV-2 infection documented by RT-PCR or with lesions suggestive&#xD;
        on chest CT.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patient (≥18 years old)&#xD;
&#xD;
          -  Patient hospitalized in surgical intensive care at the New Civil Hospital between&#xD;
             February 24 and April 15, 2020.&#xD;
&#xD;
          -  Patient with a SARS-CoV-2 infection documented by RT-PCR or with lesions suggestive on&#xD;
             chest CT.&#xD;
&#xD;
          -  Patient who has given his consent for the use of his data for the purposes of this&#xD;
             research&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient without documentation of SARS-CoV-2 infection (RT-PCR or chest scanner)&#xD;
&#xD;
          -  Patient who expressed his opposition to participating in the study&#xD;
&#xD;
          -  Subject under safeguard of justice&#xD;
&#xD;
          -  Subject under guardianship or guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Walid Oulehri, MD</last_name>
    <phone>33 3 69 55 12 71</phone>
    <email>walid.oulehri@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Saïd CHAYER, PhD, HDR</last_name>
    <phone>33 3 88 11 66 90</phone>
    <email>said.chayer@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Strasbourg University Hospitals - Anesthesia and surgical resuscitation service</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walid Oulehri, MD</last_name>
      <phone>33 3 69 55 12 72</phone>
      <email>walid.oulehri@chru-strasbourg.fr</email>
    </contact>
    <contact_backup>
      <last_name>Saïd CHAYER, PhD, HDR</last_name>
      <phone>33 3 88 11 66 90</phone>
      <email>said.chayer@chru-strasbourg.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Walid Oulehri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charlotte POUSSARDIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>François SEVERAC, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 21, 2020</study_first_submitted>
  <study_first_submitted_qc>December 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2020</study_first_posted>
  <last_update_submitted>December 23, 2020</last_update_submitted>
  <last_update_submitted_qc>December 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rehabilitation</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>COVID-19</keyword>
  <keyword>Neurological function</keyword>
  <keyword>Respiratory disorder</keyword>
  <keyword>Intensive care unit</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

